Clinical trials: Immunoglobulin
Paediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS)
Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)
The study is to provide reliable estimates of the effect of study treatment on hospital length of stay through to 28 days after randomisation.
- Trial name
- NCT04826588
- Testing
- Methylprednisolone sodium succinate 10 mg/kg intravenously, Human normal immunoglobulin (IVIg)
- Where
- 10 sites in Switzerland
- Volunteers
- 76 people
- Sponsor
- University Children's Hospital Basel
HIV Infections
The Safety and Effectiveness of Human Monoclonal Antibody, F105, in the Treatment of HIV
To determine the safety and pharmacokinetics of F105 human monoclonal antibody both following a single dose and during intermittent administration in HIV-infected patients.
- Trial name
- NCT00001105
- Testing
- F105 Monoclonal Antibody (Human)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
AL Amyloidosis
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
This will be a systematic, combined, prospective assessment of the novel echographic, CMR, and PET imaging tools in newly-diagnosed patients with cardiac AL amyloidosis at baseline and after treatment.
- Trial name
- NCT04392960
- Testing
- [18F]Florbetaben
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Advanced Malignant Tumors
A Study of AK112 in Advanced Malignant Tumors
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117（Anti-CD47 Antibody）with or without chemotherapy in advanced malignant tumors
- Trial name
- NCT05214482
- Testing
- AK112, AK117, Chemotherapy
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Akeso
Amyloidosis
Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis
The investigators expect to enroll 15 participants with relapsed or refractory IgM-associated AL amyloidosis onto this Phase II clinical trial.
- Trial name
- NCT02590588
- Testing
- Idelalisib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- John Mark Sloan
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC
This is an open-label, single-arm, multi-center, phase 2 Study to evaluate SHR-1210(anti-PD-1 antibody) in in adult Chinese patients with advanced or metastatic non-small cell lung cancer who failed or progressed to prior…
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms Nec, Lung Disease
- Trial name
- NCT03085069
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
The investigators intend to compare Epstein-Barr virus antibody and Epstein-Barr virus DNA screening efficacy in first-degree relatives of nasopharyngeal carcinoma patients.
- Trial name
- NCT05447169
- Testing
- EBV antibodies test, EBV DNA test
- Where
- China
- Volunteers
- 11,625 people
- Sponsor
- Sun Yat-sen University
Crohn's Disease
A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease
The primary aim of this study is allow the patients suffering from Crohn's disease , who both completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from the treatment, to receive treatment with…
- Trial name
- NCT00358683
- Testing
- Certolizumab pegol
- Sponsor
- UCB Pharma
Japanese Encephalitis
Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis
Japanese encephalitis is caused by a viral infection of the brain transmitted by the bite of an infected mosquito. Patients with Japanese encephalitis can rapidly develop worsening conscious level and seizures.
- Trial name
- NCT01856205
- Testing
- Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]
- Where
- 2 sites in Nepal
- Volunteers
- 22 people
- Sponsor
- University of Liverpool
Macular Degeneration
Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration
This study will evaluate visual improvement in patients treated with Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) or placebo who have Age-Related Macular Degeneration (AMD) with occult…
- Trial name
- NCT00220805
- Testing
- Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 7 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Grifols Therapeutics LLC
Pertussis, Whooping Cough
Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection
OBJECTIVES: Assess the efficacy of a single infusion of a high titer pertussis immune globulin for the treatment of severe pertussis in children.
- Trial name
- NCT00004422
- Testing
- immune globulin
- Volunteers
- 174 people
- Sponsor
- IWK Health Centre
Non-small Cell Lung Cancer, NSCLC
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent…
- Trial name
- NCT04746924
- Testing
- Tislelizumab, Ociperlimab, Pembrolizumab
- Where
- 218 sites in United States, Argentina and 17 more
- Volunteers
- 669 people
- Sponsor
- BeiGene
Heart Failure
Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide
Primary Trial objectives: To evaluate the pharmacokinetics and -dynamics of five strengths of COR-1 (10, 40, 80, 160, 240 mg) in 50 healthy, male volunteers after single intravenous administration (8 subjects on verum per dose…
- Trial name
- COR-1-01 (NCT01043146)
- Testing
- COR-1
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Corimmun GmbH
Chondrosarcoma
A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma
There is no standard treatment for chondrosarcoma. Some small sample of studies has shown that anti-angiogenic TKIs show certain activity in the treatment of chondrosarcoma.
- Trial name
- NCT05193188
- Testing
- Anlotinib hydrochloride, PD-1 inhibitor
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Antiphospholipid Syndrome
Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome
Antiphospholipid antibody syndrome (APS) is characterized by the presence of antiphospholipid antibodies, which are proteins in the blood that interfere with the body's ability to perform normal blood clotting.
- Trial name
- APS (NCT00482794)
- Where
- United States
- Volunteers
- 2,800 people
- Sponsor
- Duke University
Antiphospholipid Syndrome in Pregnancy
Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome?
This study will address the value of adding intralipid infusion in reducing pregnancy complications related to antiphospholipid syndrome
- Trial name
- NCT04274803
- Testing
- Intralipid, 20% Intravenous Emulsion, Conventional therapy of antiphospholipis syndrome
- Where
- Egypt
- Sponsor
- Tanta University
Esophageal Squamous Cell Carcinoma
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line treatment in participants with programmed cell death protein-ligand 1 (PD-L1) tumor area positivity (TAP) ≥ 10% unresectable…
- Trial name
- AdvanTIG-203 (NCT04732494)
- Testing
- Tislelizumab, Ociperlimab
- Where
- 86 sites in China, France and 4 more
- Volunteers
- 125 people
- Sponsor
- BeiGene
Mevalonate Kinase Deficiency
Geranylgeraniol Supplementation in Patients With Mevalonate Kinase Deficiency
Mevalonate kinase deficiency (HyperIgD syndrome, HIDS) is an inborn error of immunity caused by a block in the mevalonate pathway.
- Trial name
- NCT06497829
- Testing
- geranylgeraniol
- Where
- Czechia
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University Hospital, Motol
Systemic Light Chain Amyloidosis
BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis
This is a prospective, single-arm, single-center clinical study designed to evaluate the efficacy and safety of low-dose BCMA/CD3 bispecific antibody (CM336) in patients newly diagnosed with systemic light chain (AL) amyloidosis.
- Trial name
- AL-003 (NCT07151690)
- Testing
- anti-BCMA/CD3 bispecific antibody
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Mesothelioma, Pleural Mesothelioma
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Patients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed) given with durvalumab, a type of immunotherapy, or a treatment chosen by the…
- Conditions
- Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
- Trial name
- DREAM3R (NCT04334759)
- Testing
- Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab
- Where
- 57 sites in United States, Australia and 1 more
- Volunteers
- 214 people
- Sponsor
- PrECOG, LLC.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.